Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
Stocks in this Quantisnow insightHealth Care
Historical context for MAZE
Across the 9 sessions after earlier MAZE headlines, the stock closed higher 5 times and lower 4 times, with a median move of 2.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | MAZE | SPY |
|---|---|---|---|
| Mar 18, 2026 | Truist initiated coverage on Maze Therapeutics with a new price target | -3.8% | -1.4% |
| Mar 10, 2026 | Mizuho initiated coverage on Maze Therapeutics with a new price target | +13.3% | -0.2% |
| Feb 25, 2026 | Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference | +4.3% | +0.8% |
| Feb 4, 2026 | Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 | +0.4% | -0.5% |
| Jan 5, 2026 | Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference | -2.9% | +0.7% |
| Dec 4, 2025 | Wells Fargo initiated coverage on Maze Therapeutics with a new price target | +2.7% | +0.1% |
Quantisnow market dataNASDAQ
MAZE
Maze Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2025
Get push alerts for MAZE
Full MAZE profile on Quantisnow Follow MAZE and get a push notification the moment its next story breaks.